Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients

Transplant Proc. 1996 Aug;28(4):2214-7.

Authors

R L Lewis¹, D M Canafax, K G Pettit, J DiCesare, D J Kaniecki, R J Arnold, M S Roberts

Affiliation

¹ Department of Renal Transplantation, Loyola University Medical Center, Maywood, Illinois 60153, USA.

PMID: 8769203

No abstract available

Publication types

Clinical Trial
Comparative Study
Controlled Clinical Trial

MeSH terms

Administration, Oral
Adult
Cadaver
Cohort Studies
Cost-Benefit Analysis
Costs and Cost Analysis
Cyclosporine / administration & dosage
Cyclosporine / economics*
Cyclosporine / therapeutic use*
Dosage Forms
Graft Rejection / epidemiology
Graft Survival
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / economics*
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation / economics
Kidney Transplantation / immunology*
Kidney Transplantation / physiology
Length of Stay
Markov Chains*
Tissue Donors
United States

Substances

Dosage Forms
Immunosuppressive Agents
Cyclosporine